Ruxolitinib ose molelaiti Janus kinase inhibitor o loʻo faʻaaogaina i le togafitiga o le myelofibrosis maualuga poʻo le maualuga ma faʻamaʻi faʻamaʻi o le polycythemia vera ma faʻamaʻi pipisi-vs-host. Ruxolitinib e fesoʻotaʻi ma faʻalavelave faʻafuaseʻi ma e masani ona faʻafefe i le serum aminotransferase i le taimi o togafitiga ma e seasea lava faʻamaʻi faʻamaʻi, faʻamaʻi faʻamaʻi faʻamaʻi manua o le ate faʻapea foʻi ma mataupu o le toe faʻafouina o le hepatitis B i tagata faʻamaʻi.

O le Ruxolitinib o se fa'ato'aga o le Janus-associated kinase (JAK) e mafai ona tu'u tautala fa'atasi ai ma gaioiga fa'atosina ma fa'ama'i. Ruxolitinib faʻapitoa e fusifusia ma faʻalavelaveina polotinityrosinekinases JAK 1 ma le 2, lea e mafai ona oʻo atu ai i le faʻaitiitia o le mumū ma le faʻalavelaveina o le faʻalauteleina o le telefoni. O le JAK-STAT (signal transducer and activator of transcription) o loʻo i ai se sao taua i le faʻailogaina o le tele o cytokines ma mea faʻatupulaia ma e aʻafia i le faʻalauteleina o le telefoni feaveaʻi, tuputupu aʻe, hematopoiesis, ma le tali atu; JAK kinases e mafai ona faʻatonutonuina i faʻamaʻi inflammatory, myeloproliferative disorders, ma faʻamaʻi eseese.

Ruxolitinib o le apyrazolesuia i le tulaga 1 e se vaega 2-cyano-1-cyclopentylethyl ma i le tulaga 3 e se pyrrolo [2,3-d] pyrimidin-4-yl vaega. Fa'aaogaina e fai ma masima phosphate mo le togafitia o tagata mama'i e maua i le myelofibrosis feololo pe maualuga, e aofia ai le myelofibrosis muamua, post-polycythemia vera myelofibrosis ma le post-essential thrombocythemia myelofibrosis. E iai sona sao e fai ma sui o le antineoplastic ma se EC 2.7.10.2 (polotini e le fa'apitoa-tyrosinekinase) inhibitor. O le nitrile, apyrrolopyrimidinema se sui o pyrazoles.